Q-omics provides the consensus-scored ABHD18 profile across patient tissues and cancer cell-line models. ABHD18 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ABHD18 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, ABHD18 RNA expression shows 20,842 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SKCM, THCA, and ACC as cancer lineages where ABHD18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABHD18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABHD18 survival associations across molecular data types. ABHD18 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABHD18 RNA expression–survival associations across cancer types. High ABHD18 expression shows unfavorable associations in UVM and LGG, but favorable associations in SKCM, COAD, READ and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for ABHD18 RNA expression.
This table summarizes ABHD18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ABHD18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABHD18 shows lower tumor expression in THCA, KIRP and KICH and higher tumor expression in STAD, LUAD and BRCA. The THCA box plot shows higher ABHD18 RNA expression in normal versus tumor tissue (log2 FC = −0.472, t-test p < 0.001).
This table shows molecular features associated with ABHD18 in patient tissues and cancer cell lines. In patient samples, ABHD18 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ABHD18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
